Read more
Pancreatic cancer is a formidable disease, and advances in early detection and improved therapeutics have been slow to come forth. With new advances in molecular genetics in the field of pancreatic tumorigenesis, it is an opportune time to use these recent discoveries to enhance our understanding of pancreatic cancer biology and to improve outcomes in patients.
In this volume, leading experts in the field shed light on these findings describing the mutational landscape of pancreatic cancer, including new inroads into our understanding of familial pancreatic cancer, epidemiology, the biology of K-ras signaling, and the emerging contribution of epigenetic alterations to disease initiation and progression. The distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation, hallmark mutations, EMT, and cancer stem cells is described, and implications of these interactions in the context of development of novel, personalized therapeutic options are explored.
List of contents
Genomic Alterations in Sporadic Pancreatic Cancer.- Molecular Pathology of Pancreatic Cancer Precursor Lesions.- Genetic Epidemiology and Pancreatic Cancer.- Translational Implications of Molecular genetics for Early Diagnosis of Pancreatic Cancer.- The Biology of K-Ras Signaling Pathways in Pancreatic Cancer.- Molecularly Targeted Therapies in Pancreatic Cancer.- Mouse Models of Pancreatic Cancer.- Genetics of Pancreatic Cancer Metastasis.- Epigenetic Alterations in Pancreatic Cancer.- New technologies in Molecular Characterization of Pancreatic Cancer.- Index.
Summary
Pancreatic cancer is a formidable disease, and advances in early detection and improved therapeutics have been slow to come forth. With new advances in molecular genetics in the field of pancreatic tumorigenesis, it is an opportune time to use these recent discoveries to enhance our understanding of pancreatic cancer biology and to improve outcomes in patients.
In this volume, leading experts in the field shed light on these findings describing the mutational landscape of pancreatic cancer, including new inroads into our understanding of familial pancreatic cancer, epidemiology, the biology of K-ras signaling, and the emerging contribution of epigenetic alterations to disease initiation and progression. The distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation, hallmark mutations, EMT, and cancer stem cells is described, and implications of these interactions in the context of development of novel, personalized therapeutic options are explored.
